In Reply We appreciate the letter from Dr Coriat and colleagues in response to our recent report on the combination of hepatic arterial infusion chemotherapy (HAIC) with sorafenib.1 We would like to thank them for their interest in our study. In their letter, they raised 2 issues for discussion: (1) restricting the use of the hepatic arterial infusion strategy to an oxaliplatin-based regimen and to patients with portal vein tumor thrombosis and (2) evaluating HAIC with gemcitabine plus oxaliplatin (GEMOX) with sorafenib.